Early Dose Reduction or Discontinuation vs Maintenance Antipsychotics After First Psychotic Episode Remission: A...

Area of Science:

• Psychiatry and Mental Health
• Clinical Trials
• Pharmacology

Background:

• Early remission from first-episode psychosis (FEP) presents a critical juncture for treatment decisions.
• Dose reduction or discontinuation (DRD) after remission is associated with increased short-term relapse risk.
• Long-term functional outcomes following DRD in FEP remain controversial due to conflicting study findings.

Purpose of the Study:

• To compare the short- and long-term effects of DRD versus maintenance antipsychotic medication over a 4-year period in patients with FEP.
• To evaluate the impact of DRD on functioning, relapse rates, symptom severity, and quality of life.

Main Methods:

• The Handling Antipsychotic Medication Long-Term Evaluation of Targeted Treatment (HAMLETT) study was a pragmatic, single-blind, randomized clinical trial.
• 347 remitted FEP patients were randomized (1:1) to either early DRD within 12 months of remission or 12 months of maintenance treatment.
• Outcomes included patient-rated functioning (WHODAS-2), researcher-rated functioning (GAF), quality of life, relapse, and symptom severity (PANSS).

Main Results:

• In the first year, DRD was linked to a higher relapse risk (OR=2.84) and lower quality of life.
• From year 3 onwards, DRD showed significantly better researcher-rated global functioning (GAF) and a trend towards improved symptom severity (PANSS).
• Serious adverse events were similar, but 3 suicides occurred in the DRD group versus 1 in the maintenance group.

Conclusions:

• DRD in FEP carries short-term risks of relapse and reduced quality of life.
• However, DRD may lead to improved functioning and symptom control in the longer term, potentially due to enhanced coping skills.
• The decision for DRD requires careful balancing of short-term risks against potential long-term benefits and patient empowerment.